AP2M1 and acute myeloid leukemia: Stem cell transplantation, anthracycline drugs such as idarubicin or daunorubicin, and targeted therapies like midostaurin, ivosidenib, or enasidenib are being utilized.[41, 42, 43, 44, 45, 46] However, these treatments are limited by high risks of complications, including graft‐versus‐host disease, toxic side effects, resistance, and effectiveness confined to specific molecular subtypes.[41, 47, 48, 49, 50] In response to the necessity for additional therapeutic agents, our results suggest AP2M1 as a clinically applicable candidate in AML.